X4 Pharmaceuticals (NASDAQ:XFOR) Issues Quarterly Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) posted its quarterly earnings results on Tuesday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.14, Zacks reports. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. The business had revenue of $2.57 million during the quarter, compared to analyst estimates of $1.68 million.

X4 Pharmaceuticals Trading Up 1.8%

NASDAQ:XFOR traded up $0.08 during mid-day trading on Wednesday, reaching $4.31. 24,597 shares of the company’s stock traded hands, compared to its average volume of 482,904. X4 Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $9.56. The firm has a market capitalization of $376.43 million, a price-to-earnings ratio of -0.42 and a beta of 0.43. The company has a debt-to-equity ratio of 1.23, a current ratio of 5.65 and a quick ratio of 5.48. The company has a 50 day moving average price of $3.66 and a 200-day moving average price of $3.61.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Stifel Nicolaus set a $10.00 price target on X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 5th. Guggenheim started coverage on X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 price target on the stock. Zacks Research downgraded X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Finally, Wall Street Zen lowered X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.88.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. purchased a new stake in X4 Pharmaceuticals in the fourth quarter worth $267,000. Balyasny Asset Management L.P. purchased a new position in X4 Pharmaceuticals during the 4th quarter valued at $258,000. Barclays PLC purchased a new position in X4 Pharmaceuticals during the 4th quarter valued at $230,000. Jane Street Group LLC raised its holdings in X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC bought a new position in X4 Pharmaceuticals in the 4th quarter worth $173,000. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.